MarginsXMarginsX
Home › Markets › Health Care › SBFM

Sunshine Biopharma Inc. (SBFM)

SBFM trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$2.60
-3.70% on the day
Market cap
$2.1M
Nano cap
Revenue · 2025
$36.3M
+4.1% on 2024
Net income · 2025
-$6.0M
-16.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1402328/000168316826002644/0001683168-26-002644-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerSBFM on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryCanada
IPO yearNot reported by the screener
SEC CIK0001402328
SEC industry codePharmaceutical Preparations
Incorporated inCO

Financials · 2025

LineValue
Revenue$36.3M
Net income-$6.0M
Operating income-$6.2M
Net margin-16.5%
Operating margin-17.2%
Revenue growth+4.1%
Cash$9.1M
Total assets$30.1M
P/E (computed)Net income was not positive
P/S (computed)0.1×

Warning signs

Cash runway
29.3 months
$14.6M cash at September 30, 2026
Share count, 1 year
+3258.3%
2025-11-13 to 2026-11-12 · +1283119.4% over 3 years
Going-concern doubt
No
10-Q filed November 12, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-12
Cash and burn$14.6M cash; operating cash flow -$1.5M a quarter.Report 2026-09-30
Shares outstanding823,772 (2026-11-12); 4,905,945 a year earlier; 25,678,290 three years earlier. 1y figure adjusted for splits (1-for-200 overall); 3y figure adjusted for splits (1-for-400000 overall).Cover page 2026-11-12
Reverse splits, 3 years4; latest 1-for-20 on 2026-10-26Source 2026-10-26
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-07-20
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorM&K CPAS, PLLC, The Woodlands, Texas, United States; changed auditors 1 time in 24 months8-K 4.01 2025-09-30
Late filings, 12 months1 NT noticeNT 10-K 2026-03-31
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$9.4M-$1.2M-$1.4M$14.6MNo debt tags$35.4M10-Q 2026-11-12
Q2 2026
2026-06-30
$9.3M-$1.6M-$918K$13.7MNo debt tags$35.3M10-Q 2026-08-13
Q1 2026
2026-03-31
$8.1M-$1.2M-$2.1M$6.9MNo debt tags$35.5M10-Q 2026-05-13
Q4 2025
2025-12-31
$8.6M-$2.1M-$1.6M$9.1M$0$36.3M10-K 2026-04-03
Q3 2025
2025-09-30
$9.4M-$884K-$747K$9.3MNo debt tags$37.3M10-Q 2026-11-12
Q2 2025
2025-06-30
$9.4M-$1.8M-$1.3M$10.3MNo debt tags$36.3M10-Q 2026-08-13
Q1 2025
2025-03-31
$8.9M-$1.2M-$1.7M$8.1MNo debt tags$36.2M10-Q 2026-05-13
Q4 2024
2024-12-31
$9.6M-$2.2M-$3.4M$9.7M$0$34.9M10-K 2026-04-03

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
PROSPECTUS
424B42026-10-09
Latest annual report
FORM 10-K FOR DEC 2025
10-K2026-04-03
Latest quarterly / interim
FORM 10-Q FOR SEP 2026
10-Q2026-11-12
Latest current report
CURRENT REPORT
8-K2026-10-14
Latest proxy
FORM DEFA14A
DEFA14A2026-11-13

Source: SEC EDGAR submissions feed, 432 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-0.4%
1 month-42.8%
3 months-88.8%
Year to date-98.9%
1 year-99.2%
From 52-week high-99.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
DCOYDecoy Therapeutics Inc.$0.9010-7.61%$2.1M
CMNDClearmind Medicine Inc. Common Shares$4.18-7.67%$2.1M
JUNSJupiter Neurosciences Inc.$1.70-8.11%$2.2M
PPCBPropanc Biopharma Inc.$1.89-2.62%$2.0M
ONCOOnconetix Inc.$2.91-9.35%$1.9M
XRTXXORTX Therapeutics Inc. Common Shares$1.04-5.45%$1.9M
PRFXPRF Technologies Ltd.$0.6948-11.22%$2.4M
GNPXGenprex Inc.$1.90-8.65%$2.5M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier